Cargando…

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

BACKGROUND: The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards. However, the growth in the number of licensed orphan medicinal products (OMPs) has led to concerns...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pijeira Perez, Yankier, Wood, Eifiona, Hughes, Dyfrig A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621215/ https://www.ncbi.nlm.nih.gov/pubmed/37915031 http://dx.doi.org/10.1186/s13023-023-02956-3

Ejemplares similares

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
por: Varnava, Alice, et al.
Publicado: (2018)

Opportunity costs and local health service spending decisions: a qualitative study from Wales
por: Karlsberg Schaffer, Sarah, et al.
Publicado: (2016)

Impact of Relaxing Covid-19 Social Distancing Measures on Rural North Wales: A Simulation Analysis
por: Hughes, Rhodri P., et al.
Publicado: (2020)

Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study
por: Hughes, Dyfrig A., et al.
Publicado: (2016)

Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group
por: Keeping, Stuart, et al.
Publicado: (2019)

Orphan drugs expenditure in the Netherlands in the period 2006–2012
por: Kanters, Tim A, et al.
Publicado: (2014)

Renal transplant patients’ preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment
por: Hagemi, Anke, et al.
Publicado: (2017)

Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data
por: Hill‐McManus, Daniel, et al.
Publicado: (2022)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

A systematic review of economic evaluations of advanced therapy medicinal products
por: Lloyd‐Williams, Huw, et al.
Publicado: (2020)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009)

Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales
por: Gillespie, David, et al.
Publicado: (2021)

Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales
por: Gillespie, David, et al.
Publicado: (2022)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011)

Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
por: Picavet, Eline, et al.
Publicado: (2013)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Cost of health inequality to the NHS in Wales
por: Kadel, Rajendra, et al.
Publicado: (2022)

History of Medicine Society of Wales
Publicado: (1973)

Wales and medicine. An historical survey
Publicado: (1976)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Disentangling the Cost of Orphan Drugs Marketed in the United States
por: Althobaiti, Hana, et al.
Publicado: (2023)

Precision Medicines’ Impact on Orphan Drug Designation
por: Mueller, Christine M., et al.
Publicado: (2019)

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
por: Asukai, Yumi, et al.
Publicado: (2010)

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
por: Hollak, Carla EM, et al.
Publicado: (2011)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Effectiveness, safety and costs of orphan drugs: an evidence-based review
por: Onakpoya, Igho J, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care
por: Holmes, Emily A. F., et al.
Publicado: (2018)

The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Development of orphan vaccines: an industry perspective.
por: Lang, J, et al.
Publicado: (1999)

Outcomes and costs of blunt trauma in England and Wales
por: Christensen, Michael C, et al.
Publicado: (2008)

The Cost of the National Health Service in England and Wales
por: Tredgold, R. F.
Publicado: (1956)

The Cost of Cardiac Rehabilitation Services in England and Wales
por: Gray, Alastair M, et al.
Publicado: (1997)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2s5fscf6jpo0058bkjasaidi7r